Curran Terrie's Form 4 filing
Phathom Pharmaceuticals, Inc. (PHAT) · filed Jan 20, 2023
- Accession no.
- 0001209191-23-004341
- Filed
- Jan 20, 2023
- Trade date
- Jan 19-20, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $47.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Curran TerrieCIK 0001690298 | Director, Officer (President and Chief Executive) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 19, 2023 | Common Stock | AGrant or awardAcquired | +97,500 | $0.00 | $0 | 182,628 | Direct | |
| Jan 20, 2023 | Common Stock | SSaleDisposed | −5,821 | $8.20 | −$47,732.2 | 176,807 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 19, 2023 | Common Stock | AGrant or awardAcquired | +162,500 | $0.00 | $0 | 162,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.